Common Contracts
10 similar Underwriting Agreement contracts by Arcus Biosciences, Inc., Apellis Pharmaceuticals, Inc., Ayala Pharmaceuticals, Inc., others
LUCID GROUP, INC. (a Delaware corporation) 262,446,931 Shares of Class A Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 18th, 2024 • Lucid Group, Inc. • Motor vehicles & passenger car bodies • New York
The Company understands that BofA proposes to make a public offering of the Securities as soon as BofA deems advisable after this Agreement has been executed and delivered. Ayar Third Investment Company (“Ayar”) has agreed to purchase 374,717,927 shares of Common Stock from the Company pursuant to the Subscription Agreement between Ayar and the Company, dated as of the date hereof (the “Ayar Agreement”), as Placement Shares (as defined in the Ayar Agreement) with respect to the transactions contemplated hereby (the “Ayar Investment”).
bluebird bio, Inc. 95,833,332 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • December 20th, 2023 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
bluebird bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 83,333,333 shares (the “Firm Securities”) of common stock, par value $0.01 per share (“Stock”) and, at the election of the Underwriters, up to 12,499,999 additional shares of Stock (the “Optional Securities”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
FIRST WATCH RESTAURANT GROUP, INC. (a Delaware corporation) [4,500,000] Shares of Common Stock FORM OF UNDERWRITING AGREEMENTUnderwriting Agreement • September 12th, 2022 • First Watch Restaurant Group, Inc. • Retail-eating places • New York
Apellis Pharmaceuticals, Inc. 7,446,809 Shares Common Stock ($0.0001 par value per share) Underwriting AgreementUnderwriting Agreement • March 25th, 2022 • Apellis Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Apellis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 7,446,809 shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,117,021 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the contex
Decibel Therapeutics, Inc. [________] Shares Common Stock ($0.001 par value per share) Underwriting AgreementUnderwriting Agreement • February 8th, 2021 • Decibel Therapeutics, Inc. • Pharmaceutical preparations • New York
Arcus Biosciences, Inc. 11,000,000 Shares Common Stock ($0.0001 par value per share) Underwriting AgreementUnderwriting Agreement • May 29th, 2020 • Arcus Biosciences, Inc. • Pharmaceutical preparations • New York
RADIAN GROUP INC. (a Delaware corporation)Underwriting Agreement • May 15th, 2020 • Radian Group Inc • Surety insurance • New York
Radian Group Inc., a Delaware corporation (the “Company”), confirms its agreement with each of RBC Capital Markets, LLC and Goldman Sachs & Co. LLC and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 12 hereof), for whom RBC Capital Markets, LLC and Goldman Sachs & Co. LLC are acting as representatives (in such capacity, the “Representatives”), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective principal amounts set forth in said Schedule A of $525,000,000 aggregate principal amount of the Company’s 6.625% Senior Notes due 2025(the “Securities”). The Securities are to be issued pursuant to the provisions of a Senior Indenture, dated as of March 4, 2013 (the “Base Indenture”), as supplemented by the Seventh Supplemental Indenture, to be dated as of May 15, 2020 (the “Supple
Ayala Pharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This letter agreement is being delivered to you in connection with the proposed underwriting agreement (the “Underwriting Agreement”), among Ayala Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of you as representatives (the “Representatives”) of a group of Underwriters named therein, relating to an underwritten public offering of Common Stock, $0.01 par value (the “Common Stock”), of the Company (the “Offering”).
Arcus Biosciences, Inc. [●] Shares Common Stock ($0.0001 par value per share) Underwriting AgreementUnderwriting Agreement • March 5th, 2018 • Arcus Biosciences, Inc. • Pharmaceutical preparations • New York
RIVER VALLEY BANCORP (an Indiana corporation) [·] Shares of Common Stock (No Par Value Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • May 29th, 2014 • River Valley Bancorp • Savings institution, federally chartered • New York
